[CAS NO. 1235032-75-3] Bcl-xLantagonist2
PRODUCTS SPECIFICATIONS [1235032-75-3]
DESCRIPTION [1235032-75-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 436.51 |
| Molecular Formula | C21H16N4O3S2 |
| SMILES | O=C(C1=C(CN(C2=NC(C(O)=O)=CS2)CC3)C3=CC=C1)NC4=NC5=C(S4)C=CC=C5 |
Summary
Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-X L with an IC 50 and K i of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) [1] [2] .
IC50 & Target
0.091 μM (BCL-X L ) [1]
In Vivo
Assessment of Pharmacokinetics (PK) profile of Bcl-xL antagonist 2 (compound 14) in rat
[1]
.
| iv (1 mg/kg) | po (5 mg/kg) | ||
| CL p (mL/min/kg) | V ss (L/kg) | t 1/2 (h) | F % |
| 0.47 | 0.16 | 6.0 | 16 |
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 62.5 mg/mL ( 143.18 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2909 mL | 11.4545 mL | 22.9090 mL |
| 5 mM | 0.4582 mL | 2.2909 mL | 4.5818 mL |
| 10 mM | 0.2291 mL | 1.1454 mL | 2.2909 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 6.25 mg/mL (14.32 mM); Clear solution
References